Twist Bioscience Corporation (NASDAQTWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced financial results and business highlights for the first quarter fiscal 2025 ended December 31, 2024.

Twist Bioscience Corporation (NASDAQTWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced that it will issue its financial results for the fiscal 2025 first quarter ended December 31, 2024, before the opening of the market on February 3, 2025. The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time to discuss its financial results and provide an update on the company’s business. The press release with the financial results will be accessible from the company’s website prior to the conference call through the Investor Relations section under the “Company” tab at www.twistbioscience.com.

Twist Bioscience Corporation (NASDAQTWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 5:15 p.m. Pacific Time in San Francisco, California.

Cathie Wood, founder and CEO of ARK Investment Management LLC, defended the future of artificial intelligence investments while highlighting Tesla Inc. as a cornerstone of technological innovation during a recent podcast appearance with SoFi's Head of Investment Strategy, Liz Thomas.

Cathie Wood, CEO of ARK Invest, is doubling down on biologics, seeing unprecedented potential at the intersection of artificial intelligence, genetic sequencing, and gene editing technologies.

Twist Bioscience's Q4 results topped estimates, with revenue up 27% YoY. Fiscal 2025 guidance includes revenue growth and a targeted gross margin of 48%.

Twist Bioscience Corporation (NASDAQTWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced financial results and business highlights for the fourth quarter and full year fiscal 2024 ended September 30, 2024.

Twist Bioscience Corporation (NASDAQTWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Adam Laponis, CFO of Twist Bioscience, will participate in a fireside chat at the 7th Annual Evercore HealthCONx Conference on Tuesday, December 3, 2024 at 10:00 a.m. Eastern Time in Coral Gables, Florida.

As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQTWST) (“Twist” or the “Company”), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it has granted a total of 147,800 equity awards, consisting of 110,300 restricted stock units (“RSUs”) to 43 recently hired individuals and an individually negotiated award of up to 37,500 performance stock units (“PSUs”) to Colby Souders, a recently hired VP, in each case as an inducement material to their acceptance of employment with Twist. The employment inducement awards were granted under Twist’s Inducement Equity Incentive Plan and related form of restricted stock award agreement in accordance with Nasdaq Listing Rule 5635(c)(4).

The Ark Innovation and Ark Genomic ETFs turn ten years old. A look at the annual returns and current top holdings.

Collaboration brings together Absci’s Generative AI drug creation platform with Twist’s DNA synthesis platform to accelerate the design of a novel therapeutic antibody

Twist Bioscience Corporation (NASDAQTWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the launch of the FlexPrep™ Ultra-High Throughput Library Preparation Kit, designed with a proprietary Twist-developed enzyme to enable throughput at a low cost, and accelerate the adoption of NGS by microarray users in population and agricultural genomics (agrigenomics).

Twist Bioscience Corporation (NASDAQTWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2024 fourth quarter and full year ended September 30, 2024, before the opening of the market on November 18, 2024. The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time to discuss its financial results and provide an update on the company’s business. The press release with the financial results will be accessible from the company’s website prior to the conference call through the Investor Relations section under the “Company” tab at www.twistbioscience.com.

Twist Bioscience Corporation (NASDAQTWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced it has entered into a royalty purchase agreement with XOMA Royalty Corporation NASDAQ: XOMANASDAQXOMA)

Twist Bioscience Corporation (NASDAQTWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the appointment of Mike Fero, Ph.D., as chief information officer. Dr. Fero brings more than 30 years of experience leading startups, developing commercial software, researching biology and physics and working in fast-paced deep-tech businesses.

7 mid-cap stocks with impressive gains last week: CDE, MPW, NGD, RH, AUR, TWST, ALHC. Positive news and financial results drove the surge.